A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday, citing the results of an international clinical trial.
The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70 percent after three-and-a-half years.
The mortality rate was 29 percent less than when patients, all under 59 and pre-menopausal, were randomly assigned a placebo.
Lead author Sara Hurvitz said the study focused on a form of breast cancer that is fueled by the hormone estrogen and which accounts for two-thirds of all cases among younger women.
It is generally treated by therapies that block the hormone’s production.
“You actually can get synergy, or a better response, better cancer kill, by adding one of these cell-cycle inhibitors” on top of the hormone blocking therapy, Hurvitz said.
The drug works by inhibiting the activity of cancer-cell promoting enzymes. The treatment is less toxic than traditional chemotherapy, because it more selectively targets cancerous cells, blocking their ability to multiply.
Though advanced breast cancer is less common among younger women, its incidence grew 2 percent per year in the US between 1978 and 2008 for women aged 20 to 39, a previous study showed.
The new trial, which looked at more than 670 cases, included only women who had advanced cancer — stage four — for which they had not received prior hormone-blocking therapy.
“These are patients who tend to be diagnosed later, at a later stage in their disease, because we don’t have great screening modalities for young women,” Hurvitz said.
In addition, patients who develop breast cancer early tend to have more complex cases.
A pill is administered daily for 21 days followed by seven days off to allow the body time to recover, since two-thirds of patients have a moderate to severe drop in white cell count.
Jamie Bennett, a spokeswoman for Novartis, which markets the drug under the brand name Kisqali and funded the research, said it cost US$12,553 for a 28-day dose.
There is no cure for metastatic breast cancer and the majority of the women on the drug will require some form of therapy for the rest of their lives.
Oncologist Harold Burstein of the Dana-Farber Cancer Institute in Boston, who was not involved in the research, said it was “an important study,” having established that the use of the drug “translates into a significant survival benefit for women.”
“Hopefully, these data will enable access for this product for more women around the world, particularly in healthcare systems which assess value rigorously as part of their decisions for national access to drugs,” Burstein added.
Kouri Richins, a Utah mother who published a children’s book about grief after the death of her husband is to serve a life sentence for his murder without the possibility of parole, a judge ruled on Wednesday. Richins was convicted in March of aggravated murder for lacing a cocktail given to her husband, Eric Richins, with five times the lethal dose of fentanyl at their home near Park City in 2022. A jury also found her guilty of four other felonies, including insurance fraud, forgery and attempted murder for trying to poison her husband weeks earlier on Feb. 14, 2022, with a
‘PERSONAL MISTAKES’: Eileen Wang has agreed to plead guilty to the felony, which comes with a maximum sentence of 10 years in federal prison A southern California mayor has agreed to plead guilty to acting as an illegal agent for the Chinese government and has resigned from her city position, officials said on Monday. Eileen Wang (王愛琳), mayor of Arcadia, was charged last month with one count of acting in the US as an illegal agent of a foreign government. She was accused of doing the bidding of Chinese officials, such as sharing articles favorable to Beijing, without prior notification to the US government as required by law. The 58-year-old was elected in November 2022 to a five-person city council, from which the mayor is selected
DELA ROSA CASE: The whereabouts of the senator, who is wanted by the ICC, was unclear, while President Marcos faces a political test over the senate situation Philippine authorities yesterday were seeking confirmation of reports that a top politician wanted by the International Criminal Court (ICC) had fled, a day after gunfire rang out at the Philippine Senate where he had taken refuge fearing his arrest. Senator Ronald “Bato” dela Rosa, the former national police chief and top enforcer of former Philippine president Rodrigo Duterte’s “war on drugs,” has been under Senate protection and is wanted for crimes against humanity, the same charges Duterte is accused of. “Several sources confirmed that the senator, Senator Bato, is no longer in the Senate premises, but we are still getting confirmation,” Presidential
HELP DENIED? The US Department of State said that the Cuban leadership refuses to allow the US to provide aid to Cubans, ‘who are in desperate need of assistance’ US Secretary of State Marco Rubio on Wednesday said that Cuba’s leadership must change, as Washington renewed an offer of US$100 million in aid if the communist nation agrees to cooperate. Cuba has been suffering severe economic tumult led by an energy shortage that plunged 65 percent of the country into darkness on Tuesday. Cuba’s leaders have blamed US sanctions, but Rubio, a Cuban American and critic of the government established by Fidel Castro, said the system was to blame, including corruption by the military. “It’s a broken, nonfunctional economy, and it’s impossible to change it. I wish it were different,” he told
RSS